record state
frontier-ownedReview status
This finding is part of accepted frontier state. Review events, reviewable changes, and proof state explain how it can change.
unreviewed
frontiers / frontier
Finding bundle
back to staterecord state
frontier-ownedThis finding is part of accepted frontier state. Review events, reviewable changes, and proof state explain how it can change.
finding statement
finding typeNo entity list is declared.
evidence
source-boundtheoretical · manual state transition
proof impact
packet context1 reviewable changes and 0 evaluation records are attached to this finding id.
Evidence and conditions
method
manual state transition
evidence type
theoretical
conditions
Provenance
source title
FDA accelerated approval, August 2025; Jazz Pharmaceuticals regulatory announcement
authors
reviewer:will-blair
FDA grants accelerated approval to dordaviprone (August 6, 2025) for pediatric (age ≥1 year) and adult patients with progressive H3K27M-mutant DMG post-prior therapy, based on 20% objective response rate and durable disease control; first-ever systemic therapy approval for this indication.
vs_ae1d889e422fb9b7 · manual_curation
outgoing
vf_c1ccf18e8026c937Safety profile enables pediatric approval across age groups ≥1 year
events
vev_84010fb50e69a108finding.assertedManual finding added to frontier state
reviewer:will-blair · 2026-05-29
reviewable changes
vpr_de2b631f7b4db61bfinding.addManual finding added to frontier state
applied · reviewer:will-blair · 2026-05-29
evaluations
No evaluation record targets this finding id.